Mersana Therapeutics, Inc. (NASDAQ:MRSN) a biotechnology company, is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.3 per share.
For the full year, analysts predict revenues of $ 1.58 million, while looking forward to loss of $ 1.3 per share.
Previous Quarter Performance
Mersana Therapeutics, Inc. unfold loss for the second quarter of $ 0.33 per share, from the revenue of $ 0.80 million. The quarterly revenues expanded 300.00 percent compared with the same quarter last year. According to street consensus, MRSN was expected to report 2Q20 loss of $ 0.30 per share from revenue of $ 0.30 million. The bottom line results missed street analysts by $ 0.03 or 10 percent, at the same time, top line results outshined analysts by $ 0.50 million or 166.67 percent.
Stock Performance
On Friday, shares of Mersana Therapeutics, Inc. has traded high as $ 23.50 and has cracked $ 21.70 on the downward trend, reaching $ 22.38 with volume of 614.90 thousand shares.
According to the previous trading day, closing price of $ 22.38, representing a 1,032.52 % increase from the 52 week low of $ 2.06 and a 12.42 % decrease over the 52 week high of $ 26.64.
The company has a market capital of $ 1.53 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Mersana Therapeutics, Inc. will be hosting a conference call at 8:00 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.mersana.com
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications.
